Job description
What if… you could join an organization that creates, resources, and builds life sciences companies that invent breakthrough technologies to transform human health and sustainability?
Company Summary:
Quotient Therapeutics, Inc. is a privately held, early-stage company developing a novel genomics platform and therapeutics for diseases with a large unmet need.
Quotient Therapeutics, Inc. was founded by Flagship Pioneering, an innovative enterprise that conceives, creates, resources, and grows first-in-category life sciences companies. Flagship Pioneering has created over 100 groundbreaking companies over the past twenty years, all of which are pioneering novel and proprietary biological, industrial, and engineering approaches to solve major needs in human health and sustainability. These companies include Moderna (MRNA) Generate Biomedicines, Sana Biotechnology (SANA), Tessera Therapeutics, Evelo Biosciences (EVLO), Indigo Agriculture, Seres Therapeutics (MCRB), and Syros Pharmaceuticals (SYRS). To date, Flagship has deployed over $2.5 billion in capital toward the founding and growth of its pioneering companies alongside more than $19 billion of follow-on investments from other institutions. In 2021, Flagship Pioneering was ranked 12th globally on Fortune's "Change the World" list, an annual ranking of companies that have made a positive social and environmental impact through activities that are part of their core business strategies.
Position Summary:
We are seeking a Molecular Biologist to contribute to the design, adaptation and implementation of genotyping and phenotyping tools to further build Quotient's unique technology platform. The role involves the development of innovative next generation sequencing workflows, supported by a fundamental understanding of the molecular biology involved. We are looking for someone who will bring enthusiasm, intellectual curiosity, scientific rigor, and a deep-rooted desire to innovate to our team. This role is based in the vicinity of Cambridge UK and will be primarily based on site. All applicants will require permission to work in the UK.
Key Responsibilities:
- Be an active member of the technology development team, conducting bench-based experiments focused on designing or adapting cutting-edge genotyping and phenotyping tools/methods.
- Explore the scientific literature to support development of novel tools/methods to support the company's overarching goals, independently proposing, then designing and executing sets of experiments.
- Design, test and refine experimental protocols for genotyping and phenotyping for compatibility with cells or nuclei from diverse human tissues.
- Provide supervision and training for more junior lab members and/or technicians.
- Detailed recording of obtained results and communication of key findings to stakeholders across the company, both in written and presentation formats.
- Collaborate closely with other team members across the organization.
Requirements:
- PhD in molecular biology or a related field, OR 4+ years of equivalent research experience.
- Broad understanding of NGS assay workflows with hands-on experience in NGS library preparation.
- Scientific expertise in molecular biology assays including PCR, qPCR, primer design, nucleic acid purification and quantification.
- Candidates with experience in at least one of the following: (a) Development of high-sensitivity molecular techniques and tools (b) Use or development of single-cell or single-nuclei methods (c) Spatial omics methods (d) Use of multiple sequencing platforms.
- Ability to work both quickly and diligently, creating high-quality work products on schedule.
- A high degree of energy and attention to detail, and a passion for innovation and problem-solving.
- A desire to contribute to technologies that will enable the creation of transformative medicines for patients with serious diseases.
- Excellent verbal and written communication
- Ability to work successfully on interdisciplinary project teams and balance competing priorities effectively.
About Flagship
Flagship Pioneering is a biotechnology company that invents and builds platform companies, each with the potential for multiple products that transform human health or sustainability. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures, resulting in more than $90 billion in aggregate value. Many of the companies Flagship has founded have addressed humanity's most urgent challenges: vaccinating billions of people against COVID-19, curing intractable diseases, improving human health, preempting illness, and feeding the world by improving the resiliency and sustainability of agriculture. Flagship has been recognized twice on FORTUNE's "Change the World" list, an annual ranking of companies that have made a positive social and environmental impact through activities that are part of their core business strategies, and has been twice named to Fast Company's annual list of the World's Most Innovative Companies. Learn more about Flagship at www.flagshippioneering.com.
Flagship Pioneering and our ecosystem companies are committed to equal employment opportunity regardless of race, color, ancestry, religion, sex, national origin, sexual orientation, age, citizenship, marital status, disability, gender identity or Veteran status.
At Flagship, we recognize there is no perfect candidate. If you have some of the experience listed above but not all, please apply anyway. Experience comes in many forms, skills are transferable, and passion goes a long way. We are dedicated to building diverse and inclusive teams and look forward to learning more about your unique background.
Recruitment & Staffing Agencies: Flagship Pioneering and its affiliated Flagship Lab companies (collectively, "FSP") do not accept unsolicited resumes from any source other than candidates. The submission of unsolicited resumes by recruitment or staffing agencies to FSP or its employees is strictly prohibited unless contacted directly by Flagship Pioneering's internal Talent Acquisition team. Any resume submitted by an agency in the absence of a signed agreement will automatically become the property of FSP, and FSP will not owe any referral or other fees with respect thereto.